RTTNews | Dec 27, 2020 02:34AM EST

02:34 Sunday, December 27, 2020 (RTTNews.com) - Audentes Therapeutics, an Astellas genetic medicines company, said that the U.S. Food and Drug Administration lifted the clinical hold for the ASPIRO clinical trial evaluating AT132 in patients with X-linked myotubular myopathy.

X-linked myotubular myopathy or XLMTM is a serious, life-threatening neuromuscular disease characterized by extreme muscle weakness, respiratory failure, and early death.

The company said it is working to complete all clinical and regulatory activities necessary to resume dosing and plans to have discussions at a future date with the regulators on the path forward toward global registration filings for AT132.

AT132 has been granted Regenerative Medicine and Advanced Therapy, Rare Pediatric Disease, Fast Track, and Orphan Drug designations by the U.S. Food and Drug Administration, and Priority Medicines and Orphan Drug designations by the European Medicines Agency.

Read the original article on RTTNews ( https://www.rttnews.com/3156210/audentes-fda-lifts-clinical-hold-on-trial-of-at132-for-treatment-of-x-linked-myotubular-myopathy.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved